Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVERSE trial of regadenoson for microvascular dysfunction after primary PCI in STEMI
ChiCTR2400086198Phase 4Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of regadenoson in myocardial infarction (MI), Coronary Small Vessel Disease (CMD) and coronary arteriosclerosis (3 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: ST segment. Started Jun 2024; status: recruiting.
02
Drugs
regadenoson
03
Conditions
myocardial infarction (MI)Coronary Small Vessel Disease (CMD)coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR2400086198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086198.